Research Insights

With over 19 million new cancer cases and 10 million deaths reported in the year 2020, the global cancer burden continues to increase rapidly. Given the rising prevalence, researchers have made significant efforts in discovering new approaches for the treatment of oncological diseases. With several programs having entered the clinical stages, myeloid cells targeting therapeutics have emerged as a novel strategy in the suite of cancer immunotherapy approaches. Myeloid cells represent a group of c

...read more

Over the past few years, there has been an evident growth in the pipeline of cell-based products, fueled by the demand for effective therapeutics. However, such products are often temperature sensitive, requiring freezing / cryogenic conditions for transport and storage. In fact, as per a study conducted by the USFDA, across more than 80% submissions for mesenchymal cell-based therapies, it was reported that such products required cryopreservation. Therefore, there is a need to identify preserva

...read more

With several blockbuster drugs in the market and numerous others in the development pipeline, the modern biopharmaceutical industry is poised to grow at a significant pace over the coming years. The success of biopharmaceutical drugs has necessitated an upgrade of conventional biologics manufacturing equipment. As a result, the domain has witnessed several technological advancements, including the adoption of controllers and automated systems. Sensors and controllers are the essential elements o

...read more

The field of genomic data collection and analysis has evolved significantly since the introduction of a gene sequencing method by Frederick Sanger in 1977. Advances in DNA sequencing technologies have led to significant developments in a variety of healthcare-focused research fields, such as precision medicine and diagnostics. Particularly, the impact of next generation sequencing (NGS) methods, enabling whole genome and whole exome sequencing, has been the most profound. This high throughput, p

...read more

Various studies have indicated that the genetic composition of two individuals is unlikely to be similar. This can be attributed to the fact that the genetic makeup of an individual is influenced by various factors, such as family history, as well as environmental and health conditions. Therefore, one treatment cannot be expected to be successful in every patient suffering from the same disorder. It is worth highlighting that the inability to report a health issue to a medical practitioner in it

...read more

Telehealth refers to the remote delivery of healthcare services, such as medical consults, examination / interpretation of medical reports, critical health parameter monitoring, medical information sharing (between physicians and their patients) and patient education, using modern telecommunications solutions. In other words, it offers a convenient and cost-effective way for individuals with health problems to seek medical attention from the comfort of their respective homes. Currently, a wide v

...read more

With six approved drugs, namely POLIVY™ (2019), LUMOXITI™ (2018), BESPONSA® (2017), MYLOTARG™ (2017, reapproval), KADCYLA® (2013) and ADCETRIS® (2011), and more than 300 candidates in the pipeline (clinical / preclinical stages), antibody drug conjugates (ADCs) have emerged as a promising class of therapeutics for the treatment of various disease indications. Over time, medical researchers have been able to further develop their understanding of the intricacies of A

...read more

According to the National Health Interview Survey (NHIS), nearly 52% of the adult population in the US is diagnosed with at least one chronic condition, such as asthma, diabetes, and hypertension. The annual cost burden associated with chronic disorders in the US is around USD 3.7 trillion; this accounts for nearly 20% of the country’s GDP share. A major share of expenses incurred by patients living with a chronic disorder is driven by the frequent need to medicate, which may require repea

...read more

Over the past few decades, the pharmaceutical industry has witnessed significant growth, as also evident from the continuously growing pipeline of drug candidates that have been marketed or are being evaluated across several development stages. However, a recent study published in the journal of Analytical and Pharmaceutical Research has highlighted that around 90% of the candidates in the current preclinical development pipeline and more than 40% of the marketed pharmacological products are ass

...read more

The continuously growing pipeline of pharmaceutical drug candidates has inadvertently led to an increase in the demand for product packaging solutions. Further, the gradual shift of the healthcare industry from the one-drug-treats-all model to a personalized approach, coupled to the growing complexities associated with modern pharmacological interventions, has compelled packaging providers to identify innovative solutions. Since packaging material comes in direct contact with the drug, it is ess

...read more

According to experts, the global vaccines market is anticipated to generate revenues worth USD 100 billion by 2025. Data presented by the WHO indicates that the current global vaccination coverage is nearly 85% this is believed to prevent close to three million deaths from diseases, such as diphtheria, tetanus, whooping cough and measles. However, it has been reported that 25% of vaccines are damaged due to cold chain malfunction (improper distribution and shipping). In some countries, abou

...read more

Given the various advantages of cell and gene therapies and their ability to address the underlying causes of serious clinical conditions, the preference for such therapeutic modalities has increased over the years. As a result, several cell and gene therapies have been developed and approved for the treatment of a wide range of disease indications. In fact, at the time of this report’s publication, more than 30 such therapies had been approved and over 1,200 therapeutic leads are under ev

...read more

Chronic diseases are considered to be the leading causes of deaths and disability. In fact, globally, such diseases are known to be responsible for two third of the overall deaths. Within the US, nearly 52% of the adult population is presently living with at least one chronic condition, while 27% of the US adults are suffering from multiple chronic conditions. Further, the financial burden associated with these diseases is currently estimated to be around USD 1 trillion in the US; this is antici

...read more

The ongoing technological advancements, rising popularity of social media, use of virtual platforms in the ongoing COVID-19 pandemic and digitalization of the various aspects in the modern world have led to the generation of colossal amount of digital data. In fact, the amount of digital data being produced has grown exponentially over the last few years and is likely to witness significant rise in the future as well. The reliable and secure storage and accessibility of such voluminous data requ

...read more

The “Dry Age-related Macular Degeneration: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Dry Age-related Macular Degeneration.   This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual

...read more

The “Bullous Pemphigoid: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Bullous Pemphigoid.   This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elem

...read more

The “Idiopathic Short Stature: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Idiopathic Short Stature.   This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition t

...read more

The “Cushing’s Syndrome: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Cushing’s Syndrome.   This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition t

...read more

The “Familial Amyloid Polyneuropathy: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Familial Amyloid Polyneuropathy. This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In ad

...read more

The “Chronic Inflammatory Demyelinating Polyneuropathy: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy. This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market shar

...read more
  • We are your partners with no equity

  • We fit in your budget

  • We love what we do

  • Chance to prove ourselves

  • Best in class quality of work

  • Most trusted consulting partner in the industry